Repare Therapeutics Inc. presented updated data from its Phase 1 MYTHIC clinical trial, highlighting positive safety and tolerability results. The data, presented at the 36th EORTC-NCI-AACR Symposium, focused on the combination of lunresertib and camonsertib.
The analysis demonstrated a successful approach to mitigating mechanism-based anemia through an individualized schedule, while maintaining clinical benefit in heavily pretreated patients. The company observed no thrombocytopenia of any grade nor serious neutropenia in these patients.
This individualized schedule met its goal of reducing rates of Grade 3 anemia. Repare believes these data demonstrate a favorable and differentiated tolerability profile, and anticipates sharing efficacy data from the gynecological cancer expansion cohort in December 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.